Mangoceuticals
MGRX
8 hedge funds and large institutions have $147K invested in Mangoceuticals in 2025 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 2 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
2.21% less ownership
Funds ownership: 3.67% → 1.46% (-2.2%)
11% less funds holding
Funds holding: 9 → 8 (-1)
34% less capital invested
Capital invested by funds: $221K → $147K (-$74.1K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$27.2K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$21.5K |
| 3 |
Osaic Holdings
Scottsdale,
Arizona
|
+$10.4K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$8.99K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$50K |
| 2 |
HF
HRT Financial
New York
|
-$32K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$3.56K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ACA
1
Ackerman Capital Advisors
Dallas,
Texas
| $67.3K | – | – | – |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $38.2K | +$27.2K | +7,567 | +63% |
|
|
3
UBS Group
Zurich,
Switzerland
| $14.6K | +$21.5K | +5,986 | +393% |
|
|
FDCDDQ
4
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $13.8K | +$8.99K | +2,500 | +54% |
|
|
5
Osaic Holdings
Scottsdale,
Arizona
| $5.63K | +$10.4K | +2,885 | New |
|
|
SPIA
6
Steward Partners Investment Advisory
New York
| $4.08K | – | – | – |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $3.2K | -$3.56K | -990 | -38% |
|
|
8
Bank of America
Charlotte,
North Carolina
| $29 | +$14 | +4 | +36% |
|
|
VF
9
Virtu Financial
New York
| – | -$50K | -20,501 | Closed |
|
|
HF
10
HRT Financial
New York
| – | -$32K | -13,472 | Closed |
|
MGRX Hedge Fund Activity: Q1 2025 in Review
8 of the 7,463 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q1 2025, worth a combined $147K — down 34% from $221K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of MGRX and 1 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 4 added.
The largest buyer was Geode Capital Management, adding an estimated $27.2K. The largest seller was Virtu Financial, exiting entirely with an estimated $50K sold.
- 8 institutional investors held Mangoceuticals (MGRX) as of Q1 2025, down from 9 in Q4 2024.
- Funds reported $147K of Mangoceuticals stock for Q1 2025, down 34% quarter-over-quarter.
- 1 fund opened new Mangoceuticals positions in Q1 2025 and 2 closed out, a net change of -1 holder.
- The largest Mangoceuticals buyer in Q1 2025 was Geode Capital Management, an estimated $27.2K added.
- The largest Mangoceuticals seller in Q1 2025 was Virtu Financial, an estimated $50K sold.
Based on aggregated 13F filings for Q1 2025.